A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Public ClinicalTrials.gov record NCT04909801. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment With Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate
Study identification
- NCT ID
- NCT04909801
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 338 participants
Conditions and interventions
Conditions
Interventions
- Abatacept Drug
- Adalimumab Drug
- Methotrexate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 14, 2021
- Primary completion
- Jun 13, 2023
- Completion
- Aug 31, 2027
- Last update posted
- Feb 18, 2025
2021 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0036 | Fullerton | California | 92835 | — |
| Local Institution - 0086 | Los Alamitos | California | 90720 | — |
| Local Institution - 0041 | Aurora | Colorado | 80045 | — |
| Local Institution - 0058 | Cumberland | Maryland | 21502 | — |
| Local Institution - 0038 | Hagerstown | Maryland | 21740 | — |
| Local Institution - 0084 | Eagan | Minnesota | 55121 | — |
| Local Institution - 0040 | Freehold | New Jersey | 07728 | — |
| NYU Langone Ambulatory Care Brooklyn Heights | Brooklyn | New York | 11201 | — |
| Local Institution - 0082 | Wilmington | North Carolina | 28401 | — |
| Local Institution - 0127 | Portland | Oregon | 97239 | — |
| Local Institution - 0031 | Duncansville | Pennsylvania | 16635 | — |
| Local Institution - 0034 | Jackson | Tennessee | 38305 | — |
| Local Institution - 0044 | Dallas | Texas | 75231 | — |
| Local Institution - 0119 | Milwaukee | Wisconsin | 53217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04909801, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04909801 live on ClinicalTrials.gov.